Article
Gastroenterology & Hepatology
Mohamed El Kassas, Nermeen Abdeen, Dalia Omran, Mohamed Alboraie, Mohamed Salaheldin, Mohamed Eltabbakh, Rasha Farghaly, Mohammed Emadeldeen, Shimaa Afify, Ahmad Sweedy, Ahmed Ghalwash, Amr Abbass, Sameera Ezzat, Marwa Tahoon, Helmy M. ELshazly, Hassan Hamdy, Heba Omar
Summary: This study aimed to investigate the safety and efficacy of different DAAs regimens in the treatment of HCV-related decompensated cirrhosis patients. The results showed acceptable SVR12 rates and safety profiles, with younger age having a significant positive association with treatment response.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Infectious Diseases
Bo-Huang Liou, Hsin-Yun Sun, Chia-Jui Yang, Ling-Shan Syue, Yu-Lin Lee, Hung-Jen Tang, Hung-Chin Tsai, Chi-Ying Lin, Tun-Chieh Chen, Chun-Yuan Lee, Sung-Hsi Huang, Chia-Wei Liu, Po-Liang Lu, Shih-Ping Lin, Ning-Chi Wang, Aristine Cheng, Wen-Chien Ko, Shu-Hsing Cheng, Chien-Ching Hung
Summary: This study retrospectively analyzed the effectiveness and tolerability of LDV/SOF treatment in 114 HIV-positive patients with HCV GT2 coinfection, showing that LDV/SOF is effective for HIV-positive patients coinfected with HCV GT2. Some patients experienced a more pronounced decline in eGFR while receiving TDF treatment, but this was reversible after discontinuation of the drug.
INFECTIOUS DISEASES AND THERAPY
(2021)
Article
Medicine, General & Internal
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U. Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Summary: LDV/SOF therapy is effective and safe in treating Korean patients infected with hepatitis C virus (HCV), with high SVR12 rates. Most patients are infected with genotype 1, and LDV/SOF also shows efficacy for genotype 2 infection.
KOREAN JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
H. A. Elmekawy, F. Belal, A. E. Abdelaziz, K. S. Abdelkawy, A. A. Ali, F. Elbarbry
Summary: In healthy volunteers, concurrent administration of atorvastatin with fixed-dose combination of sofosbuvir/ledipasvir led to increased AUC(0-infinity) of both atorvastatin and sofosbuvir. Close monitoring for possible side effects should be employed in clinical practice after co-administration of atorvastatin and FDCSL.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Immunology
Emmanuel Weiss, Pierre de la Grange, Mylene Defaye, Juan Jose Lozano, Ferran Aguilar, Pushpa Hegde, Ariane Jolly, Lucile Moga, Sukriti Sukriti, Banwari Agarwal, Haqeeqat Gurm, Marion Tanguy, Johanne Poisson, Joan Claria, Paer-Selim Abback, Axel Perianin, Gautam Mehta, Rajiv Jalan, Claire Francoz, Pierre-Emmanuel Rautou, Sophie Lotersztajn, Vicente Arroyo, Francois Durand, Richard Moreau
Summary: Patients with ACLF exhibit dysregulation of blood immune cells, including increased neutrophils and M0-like monocytes, as well as depletion of various lymphocyte subsets. These immune cell alterations, along with defective neutrophil superoxide anion production, may contribute to immunosuppression in ACLF, highlighting potential targets for future therapies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Wan-Long Chuang, Tsung-Hui Hu, Peter Buggisch, Christophe Moreno, Wei-Wen Su, Luigi Biancone, Marianne Camargo, Robert Hyland, Sophia Lu, Brian J. Kirby, Hadas Dvory-Sobol, Anu Osinusi, Anuj Gaggar, Cheng-Yuan Peng, Chen-Hua Liu, Meghan E. Sise, Alessandra Mangia
Summary: The study demonstrated that treatment with ledipasvir/sofosbuvir was safe and effective in patients with end-stage renal disease undergoing dialysis, with 94% achieving sustained virologic response 12 weeks after treatment. Although 13% of patients experienced serious adverse events, none were related to the treatment.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Medicine, General & Internal
Ryotaro Sakamori, Ryoko Yamada, Kazuma Shinkai, Akira Doi, Yuki Tahata, Minoru Shigekawa, Takahiro Kodama, Hayato Hikita, Tomomi Yamada, Tomohide Tatsumi, Tetsuo Takehara
Summary: Achieving SVR with direct-acting antivirals resulted in improved liver function and increased skeletal muscle mass in a decompensated liver cirrhosis patient. This suggests that SVR in patients with decompensated liver cirrhosis can improve overall health outcomes.
Article
Immunology
Chun-Jen Liu, I-Shyan Sheen, Chi-Yi Chen, Wan-Long Chuang, Horng-Yuan Wang, Kuo-Chih Tseng, Ting-Tsung Chang, Jenny Yang, Benedetta Massetto, Vithika Suri, Gregory Camus, Deyuan Jiang, Fangqiu Zhang, Anuj Gaggar, Tsung-Hui Hu, Yu-Chun Hsu, Gin-Ho Lo, Chi-Jen Chu, Jyh-Jou Chen, Cheng-Yuan Peng, Rong-Nan Chien, Pei-Jer Chen
Summary: This study analyzed the reactivation of hepatitis B in 111 Taiwanese patients coinfected with hepatitis C during hepatitis C treatment. In most patients, hepatitis B virologic reactivation was asymptomatic; only a small proportion initiated hepatitis B treatment.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Ching-Chu Lo, Chung-Feng Huang, Pin -Nan Cheng, Kuo-Chih Tseng, Chi-Yi Chen, Hsing-Tao Kuo, Yi-Hsiang Huang, Chi-Ming Tai, Cheng-Yuan Peng, Ming-Jong Bair, Chien-Hung Chen, Ming-Lun Yeh, Chih-Lang Lin, Chun-Yen Lin, Pei-Lun Lee, Lee-Won Chong, Chao-Hung Hung, Te Sheng Chang, Jee-Fu Huang, Chi-Chieh Yang, Jui-Ting Hu, Chih-Wen Lin, Chun-Ting Chen, Chia-Chi Wang, Wei-Wen Su, Tsai-Yuan Hsieh, Chih-Lin Lin, Wei-Lun Tsai, Tzong-Hsi Lee, Guei-Ying Chen, Szu-Jen Wang, Chun-Chao Chang, Lein-Ray Mo, Sheng-Shun Yang, Wen-Chih Wu, Chia-Sheng Huang, Chou-Kwok Hsiung, Chien-Neng Kao, Pei-Chien Tsai, Chen-Hua Liu, Mei-Hsuan Lee, Chun-Jen Liu, Chia-Yen Dai, Wan-Long Chuang, Han-Chieh Lin, Jia-Horng Kao, Ming-Lung Yu
Summary: This study evaluated the antiviral effectiveness of ledipasvir/sofosbuvir in chronic hepatitis C patients in Taiwan and found that the treatment achieved high cure rates across different patient populations.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2022)
Article
Gastroenterology & Hepatology
Iman A. El-Baraky, Maggie M. Abbassi, Fatma S. Ebied, Mohamed Hassany, Nirmeen A. Sabry, Manal H. El-Sayed
Summary: The study found that patients with beta-thalassemia major (BTM) have lower pharmacokinetic exposure to sofosbuvir/ledipasvir (SOF/LED), which may partially explain relapses or treatment failures among BTM patients reported in other studies. BTM may be a hurdle towards implementing HCV micro-elimination model that may necessitate dose-adjustment.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2021)
Article
Virology
Toshifumi Tada, Masayuki Kurosaki, Shinichiro Nakamura, Chitomi Hasebe, Yuji Kojima, Koichiro Furuta, Haruhiko Kobashi, Hiroyuki Kimura, Chikara Ogawa, Hitoshi Yagisawa, Yasushi Uchida, Kouji Joko, Takehiro Akahane, Hirotaka Arai, Hiroyuki Marusawa, Ryoichi Narita, Yasushi Ide, Takashi Sato, Atsunori Kusakabe, Keiji Tsuji, Nami Mori, Masahiko Kondo, Akeri Mitsuda, Namiki Izumi
Summary: The study evaluated the efficacy and safety of sofosbuvir and velpatasvir interferon-free DAA therapy in HCV genotype 1- and 2-infected patients with decompensated cirrhosis. The results showed a high SVR rate of 92.3% and no severe adverse events, indicating that the SOF/VEL regimen is effective and safe in this patient population.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Virology
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hezode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Samuel
Summary: The study demonstrated that SOF/VEL plus RBV therapy for 12 weeks in patients with HCV-associated decompensated cirrhosis achieved high SVR12 rates and was generally well tolerated.
Article
Gastroenterology & Hepatology
Oidov Baatarkhuu, Jae Seung Lee, Jazag Amarsanaa, Do Young Kim, Sang Hoon Ahn, Nyamsuren Naranzul, Damba Enkhtuya, Nagir Choijamts, Purev Batbayar, Radnaa Otgonbayar, Bat-Ulzii Saruul, Chuluunbaatar Gantuul, Baljinnyam Gegeebadrakh, Narangerel Tuvshinbayar, Dorjgotov Badamsuren, Galsan Ulzmaa, Jamiyandorj Otgonbold, Kwang-Hyub Han
Summary: The efficacy and safety of LDV/SOF in Mongolian patients with genotype 1-HCV were high, with most patients achieving end of treatment response and sustained virologic response without virologic relapse. Real-world data from Mongolia may be relevant to patients in other Asian-Pacific countries.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Yuki Tahata, Hayato Hikita, Satoshi Mochida, Norifumi Kawada, Nobuyuki Enomoto, Akio Ido, Hitoshi Yoshiji, Daiki Miki, Yoichi Hiasa, Yasuhiro Takikawa, Ryotaro Sakamori, Masayuki Kurosaki, Hiroshi Yatsuhashi, Ryosuke Tateishi, Yoshiyuki Ueno, Yoshito Itoh, Taro Yamashita, Tatsuya Kanto, Goki Suda, Yasunari Nakamoto, Naoya Kato, Yasuhiro Asahina, Kentaro Matsuura, Shuji Terai, Kazuhiko Nakao, Masahito Shimizu, Taro Takami, Norio Akuta, Ryoko Yamada, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara
Summary: This study in Japan evaluated the real-world efficacy and safety of sofosbuvir plus velpatasvir (SOF/VEL) treatment for patients with hepatitis C virus (HCV)-related decompensated cirrhosis. The results showed that the treatment was effective for both compensated and decompensated cirrhosis patients, with similar outcomes to previous studies, but with risks of treatment discontinuation and liver-related deaths. Further evaluation is needed for patients with poor hepatic reserve to determine continuous improvement after viral clearance.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Yuki Tahata, Ryotaro Sakamori, Kazuki Maesaka, Akira Doi, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Masanori Miyazaki, Yasutoshi Nozaki, Akira Kaneko, Masahide Oshita, Satoshi Tanaka, Kazuho Imanaka, Naoki Hiramatsu, Naoki Morishita, Kazuyoshi Ohkawa, Takayuki Yakushijin, Mitsuru Sakakibara, Sadaharu Iio, Yoshinori Doi, Tomohide Tatsumi, Tetsuo Takehara
Summary: The aim of this study was to determine the impact of direct-acting antiviral therapy on the long-term prognosis of decompensated cirrhotic patients. Results showed that the cumulative incidence rates of decompensated events and overall survival rates were significantly better in the group receiving direct-acting antiviral therapy compared to the control group. However, there was no significant difference in the incidence of hepatocellular carcinoma between the two groups.
HEPATOLOGY RESEARCH
(2023)
